Institute of Metabolic Diseases, Guang' anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing University of Chinese Medicine, Beijing, China.
Front Endocrinol (Lausanne). 2023 May 8;14:1134297. doi: 10.3389/fendo.2023.1134297. eCollection 2023.
AIMS/HYPOTHESIS: Through a comprehensive analysis of the clinical randomized controlled trials of traditional Chinese medicine (TCM) combined with conventional western medicine (CWM) in treating type 2 diabetes(T2DM) in the past ten years, the clinical efficacy and safety of different TCMs combined with CWM were explored. This study aimed to provide specific suggestions for clinical guidance on treating T2DM.
A literature search was conducted in CNKI, WanFang, VIP, CBM, PubMed, Embase, and Web of Science. The search time was limited from 2010 to the present time. The literature type was a controlled clinical trial study of TCM combined with CWM intervention in treating T2DM. The outcome indices of the efficacy evaluation included fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c), adverse reactions, and clinical efficacy. Stata 15 and RevMan 5.4 software were used to conduct a network meta-analysis and a traditional meta-analysis.
The results showed that shenqi jiangtang granule combined with sulfonylurea, shenqi jiangtang granules combined with metformin and jinlida granules combined with insulin had significant effects on reductions in FBG, 2hPG and clinical efficacy compared with western medicines alone, which included fasting blood glucose [MD=-2.17, 95%CI=(-2.50, -1.85)], blood sugar at 2 hours after a meal [MD=-1.94, 95%CI=(-2.23, -1.65)], and clinical curative effect [OR= 1.73, 95%CI=(0.59, 2.87)].
TCM combined with CWM has a very significant effect on treating T2DM compared with CWM alone. According to the network meta-analysis, the best intervention measures of different TCMs for different outcome indicators were obtained.
identifier 42022350372.
目的/假设：通过对过去十年中中药（TCM）联合常规西药（CWM）治疗 2 型糖尿病（T2DM）的临床随机对照试验进行综合分析，探讨不同 TCM 联合 CWM 的临床疗效和安全性。本研究旨在为 T2DM 的临床治疗提供具体的指导建议。
在中国知网（CNKI）、万方、维普、中国生物医学文献数据库（CBM）、PubMed、Embase 和 Web of Science 中进行文献检索。检索时间限定为 2010 年至今。文献类型为 TCM 联合 CWM 干预治疗 T2DM 的对照临床试验研究。疗效评价的结局指标包括空腹血糖（FBG）、餐后 2 小时血糖（2hPG）、糖化血红蛋白（HbA1c）、不良反应和临床疗效。采用 Stata15 和 RevMan5.4 软件进行网络荟萃分析和传统荟萃分析。
结果表明，与西药单独治疗相比，参芪降糖颗粒联合磺脲类、参芪降糖颗粒联合二甲双胍和金芪降糖颗粒联合胰岛素对降低 FBG、2hPG 和临床疗效有显著作用，包括空腹血糖[MD=-2.17，95%CI=（-2.50，-1.85）]、餐后 2 小时血糖[MD=-1.94，95%CI=（-2.23，-1.65）]和临床疗效[OR=1.73，95%CI=（0.59，2.87）]。
与 CWM 单独治疗相比，TCM 联合 CWM 治疗 T2DM 具有非常显著的疗效。根据网络荟萃分析，得出了不同 TCM 针对不同结局指标的最佳干预措施。
标识符 42022350372。
